Expanding the Reach of INOmax EVOLVE DS Delivery System
Mallinckrodt plc, a leading global specialty pharmaceutical company, has exciting news to share regarding a significant development in neonatal healthcare. The company has now initiated a nationwide rollout of the INOmax EVOLVE™ DS delivery system, which is designed to deliver INOmax, a nitric oxide gas used for inhalation. This initiative is aimed at improving treatment options for patients and healthcare providers across U.S. hospitals.
Innovative Features of the INOmax EVOLVE DS
This next-generation delivery system integrates cutting-edge technology, enhancing its usability in the clinical environment. The INOmax EVOLVE DS combines mini-cylinder technology with automation, ensuring it meets the evolving needs of neonatal intensive care units (NICUs). Key features include an electronic blender, automated backup delivery, and a user-friendly interface, all designed to streamline care for neonatal patients.
A Commitment to Safety and Efficiency
Safety is paramount in neonatal care, and the INOmax EVOLVE DS is equipped with features that enhance patient and staff safety. With an emphasis on automation, the system provides continuous monitoring and immediate response capabilities, aiding in the prevention of potential complications linked to nitric oxide therapy.
Significance of INOmax in Neonatal Care
INOmax therapy is indicated for neonates suffering from hypoxic respiratory failure associated with pulmonary hypertension. The system is designed for use among term and near-term neonates over 34 weeks of gestation. Optimizing oxygenation and reducing reliance on more invasive procedures like extracorporeal membrane oxygenation are critical factors that can significantly improve neonatal outcomes.
Feedback from Healthcare Professionals
The INOmax EVOLVE DS Pilot program allowed healthcare professionals to provide valuable insights, ensuring the final product addresses real-world clinical needs. One respiratory therapist highlighted the impact of user-friendly design and the portability offered by the mini-cylinders, making a crucial difference in daily operations within the hospital setting.
A Proven Track Record
With more than two decades of clinical usage, INOmax has a well-established safety and efficacy profile. Over 875,000 patients have benefited from this therapy globally. The recent recognition by the Human Factors and Ergonomics Society for user-centered design further solidifies the system's innovative approach to enhancing patient care.
Availability and Support
For hospitals interested in the INOmax EVOLVE DS, collaboration with local representatives is encouraged to facilitate the integration of this technology into clinical practice. Updates and detailed product information are readily accessible on the INOmax website, ensuring healthcare professionals are well-informed.
About Mallinckrodt
Mallinckrodt is dedicated to advancing specialty pharmaceuticals and therapies that address the needs of patients with autoimmune and rare diseases. By leveraging technology and innovative solutions, the company strives to enhance treatment outcomes across various therapeutic areas.
Frequently Asked Questions
What is the INOmax EVOLVE DS system?
The INOmax EVOLVE DS is a delivery system for inhaling nitric oxide gas, aimed primarily at neonatal care.
How does the INOmax EVOLVE DS improve patient care?
The system enhances safety and automation, facilitating better patient monitoring and streamlined use in NICUs.
Who can benefit from INOmax therapy?
Neo-nates with pulmonary hypertension and hypoxic respiratory failure are the primary candidates for INOmax therapy.
What features enhance usability for healthcare professionals?
The system includes touchscreen controls, automatic functions, and compact design, making it user-friendly in hectic hospital environments.
How can one learn more about the INOmax EVOLVE DS?
Information is available through local representatives or by visiting the INOmax website for the latest updates and resources.
